24 Hours

Wantai Biopharm – The nasal spray influenza virus vector COVID-19 vaccine on clinical trial

Wantai Biopharm announced that had received the acceptance of the clinical trial application and can go to clinical trial

Wantai Biopharm (603392) announced on the evening of September 9 that the nasal spray influenza virus vector COVID-19 vaccine, which was jointly developed by the company, Xiamen University, and the University of Hong Kong, had recently received the notification of acceptance of the clinical trial application and the clinical trial approval from the National Medical Products Administration, and the product was granted for the clinical trial right. The approval was valid for 12 months. In accordance with the requirements of the clinical trial approval, the company has initiated a phase I clinical study.

Founded in 1991, Wantai BioPharm is a high-tech enterprise engaged in the research, development, and production of biological diagnostic reagents and vaccines.

Show More

Cheryl Fu

Cheryl is adept at capturing the most topical business news and has her own unique analysis. This is rare for a young person and she's offered up some really interesting ideas since joining FirmKnow Media.
Back to top button